JP2022536347A5 - - Google Patents
Info
- Publication number
- JP2022536347A5 JP2022536347A5 JP2021573426A JP2021573426A JP2022536347A5 JP 2022536347 A5 JP2022536347 A5 JP 2022536347A5 JP 2021573426 A JP2021573426 A JP 2021573426A JP 2021573426 A JP2021573426 A JP 2021573426A JP 2022536347 A5 JP2022536347 A5 JP 2022536347A5
- Authority
- JP
- Japan
- Prior art keywords
- fusion protein
- amino acid
- substitutions
- antibody
- isolated fusion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962861484P | 2019-06-14 | 2019-06-14 | |
| US62/861,484 | 2019-06-14 | ||
| PCT/US2020/037648 WO2020252421A2 (en) | 2019-06-14 | 2020-06-13 | Novel interleukin-2 variants and bifunctional fusion molecules thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022536347A JP2022536347A (ja) | 2022-08-15 |
| JP2022536347A5 true JP2022536347A5 (cg-RX-API-DMAC7.html) | 2023-08-07 |
| JP7850417B2 JP7850417B2 (ja) | 2026-04-23 |
Family
ID=73782254
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021573426A Active JP7850417B2 (ja) | 2019-06-14 | 2020-06-13 | 新規インターロイキン-2バリアントおよびその二官能性融合分子 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20220170028A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3983001A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7850417B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102978756B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN114728040A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020292421B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3143038A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020252421A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3694870A1 (en) | 2017-10-10 | 2020-08-19 | Alpine Immune Sciences, Inc. | Ctla-4 variant immunomodulatory proteins and uses thereof |
| CA3098930A1 (en) | 2018-09-21 | 2020-03-26 | Innovent Biologics (Suzhou) Co., Ltd. | Novel interleukin-2 and use thereof |
| PE20221506A1 (es) * | 2019-12-17 | 2022-10-04 | Amgen Inc | Agonista doble de interleucina-2/receptor de tnf para uso en terapia |
| KR20220140514A (ko) | 2020-01-10 | 2022-10-18 | 브라이트 피크 테라퓨틱스 아게 | 변형된 il-2 폴리펩타이드 및 그의 용도 |
| US12202882B2 (en) | 2020-05-08 | 2025-01-21 | Alpine Immune Sciences, Inc. | APRIL and BAFF inhibitory immunomodulatory proteins and methods of use thereof |
| TWI815194B (zh) | 2020-10-22 | 2023-09-11 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
| WO2022221746A1 (en) * | 2021-04-16 | 2022-10-20 | Orionis Biosciences, Inc. | Il-2 based constructs |
| KR20240034221A (ko) | 2021-07-09 | 2024-03-13 | 브라이트 피크 테라퓨틱스 아게 | 염증성 질환 및 자가면역 질환의 치료를 위한 변형된 il-2 폴리펩티드 |
| JP7864826B2 (ja) * | 2021-09-22 | 2026-05-25 | フォートビタ バイオロジクス(シンガポール)プライベート リミティド | インターロイキン2変異体およびその融合タンパク質 |
| CN118414160A (zh) * | 2021-10-06 | 2024-07-30 | 艾尔图制药公司 | 对发炎组织具有靶向特异性的白介素2嵌合构建体 |
| US20250171531A1 (en) * | 2022-02-10 | 2025-05-29 | Orionis Biosciences, Inc. | Il-2 trap molecules |
| WO2023180527A1 (en) | 2022-03-25 | 2023-09-28 | Universität Zürich | Adenoviral mediated targeting of activated immune cells |
| IL317511A (en) | 2022-06-16 | 2025-02-01 | Cephalon Llc | IL-2 immunoconjugates attenuated by anti-PD-1 antibody and their uses |
| US20260125451A1 (en) * | 2022-08-29 | 2026-05-07 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Fusion protein comprising taci polypeptide and use thereof |
| EP4689123A1 (en) * | 2023-03-29 | 2026-02-11 | WuXi Biologics Ireland Limited | Il-2 variants with improved stability and compositions thereof |
| EP4720125A1 (en) | 2023-05-30 | 2026-04-08 | Paragon Therapeutics, Inc. | Alpha4beta7 integrin antibody compositions and methods of use |
| EP4762093A1 (en) | 2023-08-14 | 2026-06-24 | Paragon Therapeutics, Inc. | Alpha 4 beta 7 integrin binding proteins and methods of use |
| EP4766723A1 (en) * | 2023-08-23 | 2026-07-01 | Depth Charge Ltd | VARIANT PROTEINS OF INTERLEUKIN-2 THAT FACILITATE COVALENT CHEMICAL CONJUGATION AND THEIR USES |
| WO2025151752A1 (en) | 2024-01-10 | 2025-07-17 | Xilio Development, Inc. | Masked il-2 cytokines and methods of use thereof |
| WO2026083295A1 (en) * | 2024-10-16 | 2026-04-23 | Bright Peak Therapeutics Ag | Trispecific compositions comprising il-2, vegf binding domains, and pd-1 binding domains |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6955807B1 (en) * | 1998-05-15 | 2005-10-18 | Bayer Pharmaceuticals Corporation | IL-2 selective agonists and antagonists |
| EP1454138B1 (en) * | 2001-12-04 | 2012-01-18 | Merck Patent GmbH | Immunocytokines with modulated selectivity |
| KR20070003934A (ko) * | 2004-03-05 | 2007-01-05 | 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 | 치료제의 환자 내약성을 예측하기 위한 시험관 내 테스트시스템 |
| CN1930300A (zh) * | 2004-03-05 | 2007-03-14 | 希龙公司 | 预测患者治疗药物耐受性的体外试验系统 |
| CN102260352B (zh) * | 2010-05-28 | 2013-11-20 | 山东先声麦得津生物制药有限公司 | 靶向性白细胞介素融合蛋白及其制备方法与应用 |
| CN105440123B (zh) * | 2011-02-10 | 2020-10-09 | 罗切格利卡特公司 | 突变体白介素-2多肽 |
| PT3102595T (pt) * | 2014-02-06 | 2019-01-11 | Hoffmann La Roche | Proteínas de fusão de interleucina-2 e suas utilizações |
| US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
| KR102379464B1 (ko) * | 2016-06-20 | 2022-03-29 | 키맵 리미티드 | 항-pd-l1 항체 |
| KR20190136076A (ko) * | 2017-04-13 | 2019-12-09 | 에프. 호프만-라 로슈 아게 | 암 치료 방법에 사용하기 위한 인터루킨-2 면역접합체, cd40 작용제 및 임의적인 pd-1 축 결합 길항제 |
| AU2018273914A1 (en) * | 2017-05-24 | 2019-11-14 | Pandion Operations, Inc. | Targeted immunotolerance |
| US20200140547A1 (en) * | 2017-05-26 | 2020-05-07 | The Johns Hopkins University | Multifunctional antibody-ligand traps to modulate immune tolerance |
| AU2019288496B2 (en) * | 2018-06-22 | 2024-11-21 | Cugene Inc. | Interleukin-2 variants and methods of uses thereof |
| JP7778571B2 (ja) * | 2019-06-05 | 2025-12-02 | アッシャー バイオセラピューティクス, インコーポレイテッド | 免疫細胞機能をモジュレートするための変異体インターロイキン-2ポリペプチドと抗原結合分子の融合体 |
-
2020
- 2020-06-13 WO PCT/US2020/037648 patent/WO2020252421A2/en not_active Ceased
- 2020-06-13 CN CN202080057566.1A patent/CN114728040A/zh active Pending
- 2020-06-13 EP EP20823570.5A patent/EP3983001A4/en active Pending
- 2020-06-13 KR KR1020227001354A patent/KR102978756B1/ko active Active
- 2020-06-13 AU AU2020292421A patent/AU2020292421B2/en active Active
- 2020-06-13 CA CA3143038A patent/CA3143038A1/en active Pending
- 2020-06-13 US US17/618,207 patent/US20220170028A1/en not_active Abandoned
- 2020-06-13 JP JP2021573426A patent/JP7850417B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022536345A5 (cg-RX-API-DMAC7.html) | ||
| JP7317159B2 (ja) | キメラ抗原受容体及びその使用方法 | |
| JP6783797B2 (ja) | 抗がん融合ポリペプチド | |
| AU2011240624B2 (en) | TRAIL R2-specific multimeric scaffolds | |
| JP2023182757A (ja) | 調整可能な親和性を有する免疫調節タンパク質 | |
| US20210380701A1 (en) | MULTIVALENT IgM- AND IgA-Fc-BASED BINDING MOLECULES | |
| JP2020191862A5 (cg-RX-API-DMAC7.html) | ||
| JP2020198875A5 (cg-RX-API-DMAC7.html) | ||
| JP2020182458A5 (cg-RX-API-DMAC7.html) | ||
| JP2023506452A5 (cg-RX-API-DMAC7.html) | ||
| JP2022504868A (ja) | 獣医学的使用のための、新生仔fc受容体(fcrn)への結合性が変化したfc変異体 | |
| JP2020511949A5 (cg-RX-API-DMAC7.html) | ||
| JP7356726B2 (ja) | タンパク性ヘテロ二量体及びその使用 | |
| KR20160014010A (ko) | 신규 항체 | |
| RS55609B1 (sr) | Fc fuzioni proteini koji sadrže nove linkere ili aranžmane | |
| CA2993891A1 (en) | Interleukin-15 fusion proteins for tumor targeting therapy | |
| WO2011076781A1 (en) | Tetravalent cd47-antibody constant region fusion protein for use in therapy | |
| WO2016124670A1 (en) | Novel binding proteins comprising a ubiquitin mutein and antibodies or antibody fragments | |
| RU2018104703A (ru) | Опухолеспецифичное антитело против egfr и его применение | |
| JP2018529327A5 (cg-RX-API-DMAC7.html) | ||
| JP2018536434A (ja) | 腫瘍形質導入のための組成物及び方法 | |
| JP2020511144A5 (cg-RX-API-DMAC7.html) | ||
| CN111423512A (zh) | 阻断血管内皮细胞生长且活化t细胞的多靶向融合蛋白和包含其的药物组合物 | |
| JP7303527B2 (ja) | 新たな結合特異性を抗体に付与する超汎用法 | |
| JP2024535872A5 (cg-RX-API-DMAC7.html) |